Merge to enter ophthalmic imaging market by purchasing OIS
This article was originally published in Clinica
Merge Healthcare, a specialist in automated healthcare data and diagnostic workflow technology, has definitively agreed to buy Ophthalmic Imaging Systems (OIS), an ophthalmic digital imaging and informatics company, for around $30.3m. Under the terms of the deal, OIS shareholders will receive 0.1693 Merge shares – equivalent to $1 – for each OIS share. The transaction is expected to close in the third quarter. Until now, Chicago, Illinois-based Merge has offered imaging solutions for radiology, cardiology and orthopaedics, a suite of products for clinical trials, software for financial and presurgical patient management, and applications for other vendors of imaging products. It identified ophthalmology as an important growth area, as demand for eye imaging is increasing due to factors such as the ageing population.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.